Hirschhorn, Daniel

Publications

Sort by

Co-Author Network

selected publications

TYRP1 directed CAR T cells control tumor progression in preclinical melanoma models. Molecular therapy. Oncology. 2024 Academic Article GET IT
Having the cake and eating it? Clofazimine boosts immunotherapy while limiting side effects. Cancer cell. 2024 Academic Article GET IT
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell. 2023 Academic Article GET IT
Times cited: 1
The ectonucleotidase CD39 identifies tumor-reactive CD8⁺ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. Immunity. 2022 Academic Article GET IT
Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. The Journal of experimental medicine. 2022 Academic Article GET IT
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. JCI insight. 2021 Academic Article GET IT
Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. Cell reports. 2021 Academic Article GET IT
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. The Journal of clinical investigation. 2019 Academic Article GET IT
Times cited: 36
Non-conventional Inhibitory CD4⁺Foxp3^-PD-1^hi T Cells as a Biomarker of Immune Checkpoint Blockade Activity. Cancer cell. 2018 Academic Article GET IT
Times cited: 121
Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells. Nature. 2016 Academic Article GET IT
Times cited: 709
The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. Advances in cancer research. 2015 Article GET IT
Times cited: 31
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. Journal for immunotherapy of cancer. 2014 Review GET IT
Times cited: 107
Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates. Cancer immunology research. 2014 Academic Article GET IT
Times cited: 43
Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients. 2013 GET IT
Times cited: 108
Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 139
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. The Journal of experimental medicine. 2012 Academic Article GET IT
Times cited: 125
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer research. 2011 Academic Article GET IT
Times cited: 313
Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PloS one. 2010 Academic Article GET IT
Times cited: 63
Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. Blood. 2010 Academic Article GET IT
Times cited: 107
Cytokine-FC fusion genes as molecular adjuvants for DNA vaccines. Methods in molecular biology (Clifton, N.J.). 2010 Academic Article GET IT
Times cited: 4
The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. The Journal of clinical investigation. 2009 Academic Article GET IT
Times cited: 65
Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. Journal of immunology (Baltimore, Md. : 1950). 2009 Academic Article GET IT
Times cited: 136
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. The Journal of experimental medicine. 2009 Academic Article GET IT
Times cited: 186
Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. The Journal of experimental medicine. 2009 Academic Article GET IT
Times cited: 94
Mechanisms of immunization against cancer using chimeric antigens. Molecular therapy : the journal of the American Society of Gene Therapy. 2008 Academic Article GET IT
Times cited: 13
Adjuvanticity of plasmid DNA encoding cytokines fused to immunoglobulin Fc domains. Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Academic Article GET IT
Times cited: 45
Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. Journal of immunology (Baltimore, Md. : 1950). 2006 Academic Article GET IT
Times cited: 154

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Targeting VISTA on neutrophils to manage immunotherapy adverse events awarded by Melanoma Research Alliance Principal Investigator 2025 - 2028

Determining the role of neutrophils in anti-tumor immunity and immune-related adverse events in the context of T cell-based therapies awarded by National Cancer Institute Co-Investigator 2025 - 2030
PICI Grant and Main Collaboration Agreement with Multiple Subprojects awarded by Parker Institute for Cancer Immunotherapy Co-Investigator 2024 - 2028
Engineered IgA engagers to fight cancer awarded by Advanced Research Projects Agency for Health Co-Investigator 2025 - 2027

Sponsored Research Agreement - Merghoub Lab awarded by ReAlta Life Sciences, Inc. Key Personnel 2023 - 2026

more ...

less ...

Background

education and training

B.S., University of Texas 96
Ph.D., University of Texas 2003

Contact

full name

Daniel Hirschhorn

primary email

dah4023@med.cornell.edu

VIVO Weill Cornell Medical College

Daniel Hirschhorn Assistant Professor of Research in Pharmacology

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email